🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer

RecruitingNAAges 18 Years - 85 YearsAllPeking University People's Hospital
NCT07894458 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is a prospective single-arm clinical trial targeting patients with stage IB-IIIA non-small cell lung cancer (NSCLC) who have received neoadjuvant immunotherapy. The primary objective is to evaluate whether a personalized follow-up and adjuvant treatment strategy-based on the combination of ctDNA-based minimal residual disease (MRD) testing and pathological response-can effectively improve the 2-year postoperative recurrence-free survival (RFS). The study will enroll 100 patients scheduled for radical surgery who have undergone neoadjuvant immunotherapy (in combination with platinum-based chemotherapy). Patients will receive individualized follow-up and adjuvant therapy based on dynamic changes in ctDNA at various preoperative and postoperative timepoints, as well as pathological response. Adjuvant therapy will be recommended if patients do not achieve pathological complete res

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Signed written informed consent. 2. Male or female, aged ≥ 18 and \< 85 years. 3. Radical resection performed, pathologic stage IB-IIIA (8th TNM) non-small-cell lung cancer. 4. Tumor tissue and blood samples obtainable at all protocol-specified time-points. 5. No pure ground-glass nodule on imaging. 6. Completed standard neoadjuvant immunotherapy combined with platinum-based chemotherapy. Exclusion Criteria: 1. Postoperative pathology shows other than NSCLC, including but not limited to benign lesions, small-cell carcinoma, metastasis, or indeterminate/inadequate histology. 2. Insufficient or poor-quality blood or tissue samples. 3. Pure ground-glass nodule on imaging. 4. History of any malignancy within the past 5 years. 5. Contraindication to surgery preventing radical resection. 6. Non-radical (R2) resection. 7. Pathologic stage IIIB-N3, IIIC, or IV on paraffin sections. 8. Refusal or withdrawal of informed consent. 9. Any condition deemed unsuitable by the investigator (e.g., perioperative blood transfusion, severe psychiatric disorder precluding follow-up).
💊

What it tests

  • Adaptive therapy of de-escalation and escalation based on MRD testing and pathological response
📍

Where

1 site
Peking University People's Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy